Answers are grounded in this paper and cite their sources.
Background The microbiota–gut–brain axis provides an emerging framework for understanding neuropsychiatric disorders. Depression and addiction, despite substantial comorbidity, are frequently investigated separately. This review examines whether gut dysbiosis contributes to vulnerability, symptom persistence and recovery through shared inflammatory, endocrine, metabolic and reward-related mechanisms. Methods A structured narrative review was conducted using PubMed/MEDLINE, Scopus, Web of Science and PsycINFO, supplemented by citation searching. Priority was given to systematic reviews, meta-analyses, human cohorts, randomised trials and mechanistic studies. Evidence was evaluated for methodological quality, confounding, replication, biological plausibility and clinical relevance. Results Convergent evidence implicates altered short-chain fatty acid production, intestinal barrier dysfunction, dysregulated tryptophan–kynurenine metabolism, systemic inflammation, hypothalamic–pituitary–adrenal-axis disturbance and altered affective and reward signalling. Human evidence is strongest for major depressive disorder and alcohol use disorder, whereas evidence involving opioids, psychostimulants, cannabis and polysubstance use remains comparatively limited. Dietary interventions, probiotics, prebiotics, synbiotics and faecal microbiota transplantation demonstrate preliminary therapeutic potential. However, methodological heterogeneity, uncertain causality, limited replication and insufficient evidence of sustained benefit prevent routine clinical recommendation. Digital phenotyping, wearable technologies and artificial intelligence may facilitate integration of microbial, metabolic, behavioural and longitudinal clinical information, although prospective validation and demonstrated clinical utility remain limited. Conclusions The proposed Microbiota–Gut–Brain–Reward framework conceptualises dysbiosis as a potentially modifiable contributor rather than an independent cause of depression or addiction. Clinical translation requires longitudinal multi-omic research, harmonised methodologies, mechanistically informed trials and integration with established pharmacological, psychological and social interventions. Digitally enabled precision approaches may support personalised recovery monitoring, provided interpretability, privacy, equity and clinical governance are prioritised. The United Arab Emirates offers opportunities for culturally responsive translational research, although implementation must remain evidence-driven, ethically governed and subject to rigorous prospective evaluation before clinical adoption.
No takes yet. Share an insight, caveat, or question.
Ismail et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: